Donor-cell leukemia post bone marrow transplantation is a rare event. Most of the cases reported to date have developed in cells from an HLA-matched sibling, who had no evidence of malignant disease before or following the occurrence of donor-origin leukemia. We describe a 17-year-old female who developed B-cell lymphoma 9 years following the occurrence of donor-origin acute myeloid leukemia in her brother for whom she had donated marrow. Cytogenetic analysis of the tumor revealed multiple chromosomal aberrations. The donor was heterozygous for the Ashkenazi mutation of Bloom's syndrome, suggesting that donor-type leukemia could have resulted from genomic instability in the donor cells. Bone Marrow Transplantation (2003) 31, 931-934.
Allogeneic bone marrow transplantation (BMT) has been increasingly used for the treatment of patients with malignant and nonmalignant disorders. With the improvement in survival, recipients have a significant risk of developing secondary malignancies including both leukemia and lymphoma. Most lymphomas arising during the first year post-transplant and are usually B-cell lymphoproliferative disorder of donor origin for which the mechanism is established and is associated with EBV infection. 1 In contrast, leukemia occurring after BMT is usually a recurrence of the original host clone. Only a few case reports have described the occurrence of leukemia in donor cells. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In most of the reports, the donor was a matched sibling, and the transplant was performed for malignant disease (acute or chronic leukemia), suggesting a genetic predisposition for the development of the donororigin malignancy. The fact that in most of the cases described the donor has had no evidence of leukemia either before or after the development of malignancy in the transplanted cells indicates that transplant-related factors are most likely to be responsible for the development of the leukemia in the donor cells.
The presented case suggests that underlying genomic instability in the donor cells may predispose them to developing hematologic malignancies.
Case report
A 17-year-old Ashkenazi Jewish woman was diagnosed with mediastinal large B-cell lymphoma in May 1999. Cytogenetic analysis of the tumor cells showed multiple chromosomal abnormalities (Figure 1 ). She was treated with six courses of chemotherapy according to the BFM-NHL protocol with a very good response. She completed chemotherapy in September 1999 without complications. She then received four courses of anti-CD 20 (Rituximab) monoclonal antibody. The patient had been evaluated for premalignant conditions and found to be heterozygous for the Ashkenazi mutation of Bloom's syndrome: 6-bp deletion/7-bp insertion at position 2281 of the BLM gene. She is now almost 3 years off therapy with no evidence of lymphoma.
Thirteen years earlier, in August 1986, the patient had donated her bone marrow to her brother who was transplanted for relapsed ALL in the Fred Hutchinson Cancer Research Center. The brother had engrafted and was well until 2 years later when he developed an isolated testicular relapse and was treated with radiation to the testes. In May 1990, he developed MDS/AML and the leukemic cells were of donor-origin based on cytogenetic analysis. All cells examined had a female karyotype and in addition displayed a pericentric inversion of chromosome 11 (46,XX,inv(11)(p15q23). One of the breakpoints in the inverted chromosome 11 was at band 11q23. In April 1991, he underwent a second transplant from another HLA-identical brother but died in May 1991 from severe veno-occlusive disease of the liver and multiorgan failure.
Discussion
The occurrence of leukemia in donor cells post transplant is a rare event for which the underlying mechanism is not defined. Its rarity may reflect the ability to identify the origin of the leukemic cells and depends on the methods used. Most of the cases reported to date have been in the setting of an HLA-matched sibling. This could include multistep carcinogenesis where an inherited primary defect in caretaker genes in both the recipient and donor predisposes to a second event, which is associated with both the conditioning regimen pretransplant and the replicative stress on the donor stem cells post transplant.
Primary defect
Genetic factors are presumed to play an important role in the development of acute leukemias. Siblings of children with leukemia have an approximately two-to four-fold increased risk of developing the disease compared to unrelated children in the general population. 17, 18 An increased risk of developing a hematological malignancy was reported in first-and second-degree relatives of patients with various hematological neoplasms in comparison with two control groups. 19 Various genomic instability syndromes (Bloom's syndrome, Fanconi's anemia, hereditary nonpolyposis colon cancer, etc.) could predispose to the development of malignancy and in particular leukemia. The patient described above was found to be a heterozygote for the Bloom's syndrome mutation. Homozygous mutation in the BLM gene results in genomic instability and predisposes patients to a wide variety of malignancies. Patients tend to develop the malignancy at an earlier age and to have multiple different cancers, both hematological and nonhematological. 20 A recent study showed that carriers of a BLM mutation have an increased risk of colorectal cancer. 21 These data, as well as the multiple chromosomal abnormalities that were found in the lymphoma cells, suggest a role of genomic instability in the development of the donor-origin leukemia and 'second' malignancy in our case.
Conditioning regimen
Another contributing factor could be transplant related such as radiation therapy, as was suggested in a mouse model. In this model, mice whose plasmacytoma regressed following treatment with melphalan developed persistent immunohematological abnormalities consistent with a premalignant condition but never developed an overt leukemia. However, when splenocytes from these mice were transferred to preirradiated normal mice, most of them developed leukemia. The leukemic cells originated from the donors according to sex chromosomes analysis. 22 These findings suggest a role for radiation in creating the necessary conditions for the progression toward leukemia. Radiation-induced microenvironment damage in addition to a stromal defect could support leukemic transformation in the donor cells. In the majority of the case reports of donor-origin leukemia, TBI was part of the conditioning regimen, as in the case reported by us. Moreover, the boy Figure 1 Cytogenetic analysis of lymphoma cells with 47-48X,ÀX,+10,À13,+21, der(4), del(6)(q26), dup(7)(q12q32), t(9;?)(p23;?), iso(18q), +iso(18q).
Arrows point to abnormal chromosomes.
Lymphoma in the donor 9 years after donor-origin AML B Bielorai et al was also treated with radiation for an isolated testicular relapse 2 years post transplant, and therefore some radiation-induced damage could have injured the transplanted donor cells.
Replicative stress
The establishment of donor-derived hematopoiesis in the recipients of allogeneic stem cell transplants requires extensive proliferation of the stem cells. Wynn et al 23 reported that young recipients of allogeneic bone marrow transplants have shorter telomeres compared to their donors. Telomere shortening is associated with replicative senescence and also with chromosomal instability, and could contribute to the development of clonal disorders.
Telomere shortening could serve as another contributing factor for the development of malignant disorder in the donor cells.
There are three reports in the literature describing the occurrence of another malignancy in the donors (Table 1) . Evidence of the malignant clone at time of transplant was shown in two of the reported cases.
The fact that the donor described by us developed the lymphoma 13 years after the bone marrow donation mitigates against the possibility that she harbored the neoplastic cells at that time and favors a role of a genetic predisposing factor.
The relative contribution of genetic and transplantrelated factors to the development of donor-origin leukemia is still unknown. To the best of our knowledge, this is the first case describing a second hematological malignancy in a donor, developing years after a donor-origin leukemia in her brother for whom she donated the marrow. Since genetic factors play an important role in the development of malignant diseases, one should consider known predisposing factors when planning the appropriate conditioning regimen. For example by avoiding the use of radiation that could contribute to the development of leukemia in a patient who already has a genetic tendency for malignant disease. 
